Drug Profile
Research programme: pain theraputics - Colby Pharmaceuticals
Alternative Names: CPC 111; CPC 123Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Colby Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 25 Jul 2016 Preclinical trials in Pain in USA (PO) before July 2016